127 related articles for article (PubMed ID: 38417401)
1. Tabersonine Enhances Olaparib Sensitivity through FHL1-Mediated Epithelial-Mesenchymal Transition in an Ovarian Tumor.
Chen X; Yan Y; Liu Y; Yi Q; Xu Z
J Nat Prod; 2024 Apr; 87(4):837-848. PubMed ID: 38417401
[TBL] [Abstract][Full Text] [Related]
2. Tabersonine enhances cisplatin sensitivity by modulating Aurora kinase A and suppressing epithelial-mesenchymal transition in triple-negative breast cancer.
Chen X; Yan Y; Liu Y; Yi Q; Xu Z
Pharm Biol; 2024 Dec; 62(1):394-403. PubMed ID: 38739003
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
4. The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell.
Chen X; Chen Y; Lin X; Su S; Hou X; Zhang Q; Tian Y
Curr Pharm Biotechnol; 2018; 19(6):506-513. PubMed ID: 30003858
[TBL] [Abstract][Full Text] [Related]
5. Biguanides in combination with olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through inhibition of Snail.
Wang Q; López-Ozuna VM; Baloch T; Bithras J; Amin O; Kessous R; Kogan L; Laskov I; Yasmeen A
Cancer Med; 2020 Feb; 9(4):1307-1320. PubMed ID: 31863638
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
Wang Z; Gao J; Ohno Y; Liu H; Xu C
Cancer Chemother Pharmacol; 2020 Feb; 85(2):273-284. PubMed ID: 31907647
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
Rytelewski M; Maleki Vareki S; Mangala LS; Romanow L; Jiang D; Pradeep S; Rodriguez-Aguayo C; Lopez-Berestein G; Figueredo R; Ferguson PJ; Vincent M; Sood AK; Koropatnick JD
Oncotarget; 2016 Apr; 7(15):20825-39. PubMed ID: 26959114
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
10. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
Zhong Q; Xiong Y; Ling C; Qian Y; Zhao X; Yang H
Exp Biol Med (Maywood); 2021 Jun; 246(11):1297-1306. PubMed ID: 34092127
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
13. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
14. Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo.
Nakamura N; Fujihara H; Kawaguchi K; Yamada H; Nakayama R; Yasukawa M; Kishi Y; Hamada Y; Masutani M
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269669
[TBL] [Abstract][Full Text] [Related]
15. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment.
Baldwin P; Ohman AW; Tangutoori S; Dinulescu DM; Sridhar S
Int J Nanomedicine; 2018; 13():8063-8074. PubMed ID: 30555227
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D
Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276
[TBL] [Abstract][Full Text] [Related]
18. Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines.
Gralewska P; Gajek A; Marczak A; Rogalska A
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638899
[TBL] [Abstract][Full Text] [Related]
19. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]